gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Feb 8, 2013 14:40:45 GMT -5
yea iam still holding, to stuborn to take that big of loss, i am about to my break even point.
Galena Biopharma, Inc: Gale, formerly RXi Pharmaceuticals Corporation, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). The Company’s Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera).
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Feb 12, 2013 13:38:48 GMT -5
I know I put this one up a while back it has been one of my long, long holds. there should be a good gain up until March and depending on the results this one could go really big. Shares of Ziopharm Oncology Inc (ZIOP). climbed Tuesday morning after the drug developer said it will go ahead with data analysis from a late-stage trial of its lead product, the potential cancer treatment palifosfamide. The New York company said the study of palifosfamide as a treatment for patients with soft tissue sarcoma, which is a cancer that forms in connective tissue, reached enough progression-free survival events to complete data collection and then analysis. Progression-free survival measures the time before a disease progresses or the patient in the study dies. The study measures how patients taking the drug fare compared to a control group. Ziopharm will announce initial results from the study in late March. The company, which focuses on developing cancer treatments, has no other products on the market. It also is studying palifosfamide in a late-stage trial for a form of lung cancer and is developing an oral capsule form of the intravenous drug.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Feb 22, 2013 14:19:49 GMT -5
MannKind:MNKD is expected to report the trial results for Afrezza, its ultra rapid insulin drug. The company's fortune depends on the performance of this drug. The results are expected to be released later this year in August. The company is promoted by Alfred Mann, who also acts as its CEO and owns 41 percent of the stock. He has previous track record as a medical entrepreneur and sold his previous venture MiniMed for $3 billion to Medtronic. Alfrezza has been declined twice by the FDA, first in 2010 and second time in 2011. However, this time the company seems to have put all its might behind the drug, which is likely to receive approval on its third attempt.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Mar 6, 2013 11:39:20 GMT -5
there is a tender offer pending on this one: Complete Genomics, Inc.GNOM: operates as a United States-based life sciences company. The Company develops and commercializes a deoxyribo nucleic acid (DNA) sequencing platform using components, chemistry, and computation to produce a human genome. Its Complete Genomics Analysis Tools (CGA Tools) is an open source project to provide tools for downstream analysis of genomics data produced by Complete Genomics. It offers solution as CGA Service and provides customers with data that is ready to be used for genome-based research. Its customers include academic and government research centers, and biopharmaceutical companies
|
|
The Virginian
Senior Member
"Formal education makes you a living, self education makes you a fortune."
Joined: Dec 20, 2010 18:05:58 GMT -5
Posts: 3,629
Today's Mood: Cautiously Optimistic
Location: Somewhere between Virginia & Florida !
Favorite Drink: Something Wet & Cold
|
Post by The Virginian on Apr 1, 2013 7:47:05 GMT -5
It seems FNMA and Freddy are merging into one company - .68 per share.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Apr 1, 2013 14:18:39 GMT -5
Navios Maritime Holdings Inc.NM: (Navios Holdings) is a global, vertically integrated seaborne shipping and logistics company focused on the transport and transshipment of drybulk commodities including iron ore, coal and grain. The Company operates in three segments: Drybulk Vessel Operations, Tanker Vessel Operations and Logistics Business. Drybulk Vessel Operations business consists of transportation and handling of bulk cargoes through ownership, operation, and trading of vessels, freight, and forward freight agreements (FFAs). The Logistics Business consists of operating ports and transfer station terminals, handling of vessels, barges and push boats, as well as upriver transport facilities in the Hidrovia region. In April 2012, it acquired the Navios Serenity, which is a Handysize vessel of 34,718 deadweight tons. In June 2012, Navios Maritime Partners L.P. purchased the Navios Buena Ventura, a 2010 South-Korean-built Capesize vessel of 179,259 dwt from the Company.
fanny and freddie merging would be a good thing
|
|
The Virginian
Senior Member
"Formal education makes you a living, self education makes you a fortune."
Joined: Dec 20, 2010 18:05:58 GMT -5
Posts: 3,629
Today's Mood: Cautiously Optimistic
Location: Somewhere between Virginia & Florida !
Favorite Drink: Something Wet & Cold
|
Post by The Virginian on Apr 1, 2013 14:48:47 GMT -5
Be careful with Navios Maritime - These tanker companies are very competitive and Cyclical
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Apr 6, 2013 10:18:13 GMT -5
this is not a penny by any means but i still hold some from when it was, this is going to be hugh: Sarepta Therapeutics ( NASDAQ: SRPT ) reported the latest clinical study results today for its Duchenne muscular dystrophy, or DMD, drug. Shares in the biotech are up nearly 5% as the trading day winds down. Latest results Sarepta's news related to results from 74 weeks into a phase 2b study of eteplirsen. Patients taking the drug demonstrated continued stabilization of walking ability on the six-minute walk test, a standard assessment of walking capability and clinical function for neuromuscular diseases. As with earlier points in this study, DMD patients taking eteplirsen showed significant improvement in walking ability compared to patients on placebo. This was true for groups taking the 30 mg/kg and 50 mg/kg dosages of the drug. Eteplirsen also continued to be well-tolerated. Sarepta reported that no patients experienced significant treatment-related adverse events or any serious adverse events. At week 62, one patient had a temporary elevation of urine protein, but that was resolved and the patient stayed in the study with no further problems. Chris Garabedian, Sarepta's president and CEO, said that the company was "encouraged to see a continued stabilization of walking ability in patients treated with eteplirsen for nearly one and a half years." Garabedian added that "these results continue to support the potential of eteplirsen to be a major advance in the treatment of DMD in altering the course of this progressive and irreversible disease."
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Apr 9, 2013 13:53:47 GMT -5
Delcath Systems, Inc. (Delcath)DCTH: is a development-stage, specialty pharmaceutical and medical device company, focused on oncology, initially cancers in the liver. Delcath focuses on the development and clinical study of the Delcath chemosaturation system. The Delcath chemosaturation system allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the targeted organ. Once the organ is isolated, the Delcath chemosaturation system delivers doses of chemotherapeutic agents directly to the liver. The Delcath chemosaturation system involves a series of three catheter insertions, each of which is placed percutaneously through interventional radiology techniques. The procedure is minimally invasive and repeatable allowing for multiple courses of treatment with chemotherapeutic drugs. On April 13, 2011, it received Conformite Europeenne (CE) mark approval for the Delcath Hepatic CHEMOSAT Delivery System (CHEMOSAT System). advistory board is may 2, fda has been changed to sept 11
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Apr 20, 2013 13:56:39 GMT -5
Aveo Pharma (AVEO)
A Food and Drug Administration (FDA) Advisory committee will convene on May 2nd to vote for or against recommending tivozanib for approval. Tivozanib is a low-molecular-weight inhibitor of the VEGF receptor designed for the treatment of metastatic renal cell carcinoma (RCC), which is more widely known as kidney cancer.
In January of this year, the company reported positive Phase III results from a study of 517 patients with RCC. The study compared tivozanib to sorafenib, which is the current front line treatment for RCC.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on May 6, 2013 15:37:55 GMT -5
GT Crystal Systems, a subsidiary of GT Advanced Technologies (Nasdaq:GTAT -1.30%, news), today announced that it has agreed with Motorola Solutions to be the exclusive supplier of sapphire screens for Motorola's new MP6000 multi-plane bioptic imager. GT Crystal Systems will fabricate the 24 square inch sapphire components in its manufacturing facility located in Salem, Mass.
"This is an important development for us as it expands the adoption of our sapphire material into a new market segment," said Tom Gutierrez, GT's president and CEO. "GT's ASF sapphire is virtually scratch-proof, making it ideally suited as a screen material over reinforced glass because it can withstand the extreme strike forces the scanner system experiences during its use. The durability and optical performance of GT's ASF sapphire material has broad applicability in other cover and touch screen applications, and we are pursuing a number of these promising opportunities."
"Motorola's first imaging-based bioptic solution, the MP6000, enhances the user experience of retailers and consumers alike by enabling quick checkout and scanning of traditional paper-based bar codes as well as bar codes delivered on the screen of a mobile device," said Bob Sanders, senior vice president, Data Capture Solutions, Motorola Solutions. "GT's ASF sapphire provides the durability and longevity needed to ensure optimal performance."
GT is actively pursuing markets for ASF grown sapphire material outside of the traditional LED and optical applications, including the smartphone segment. The company will exhibit and present its sapphire solutions at the Society for Information Display's Display Week show in Vancouver, Canada May 19-24.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on May 14, 2013 11:09:34 GMT -5
Curis, Inc. (Nasdaq:CRIS ), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced that Erivedge® (vismodegib) was approved for marketing registration by Australia's Therapeutic Goods Administration for the treatment of adult patients with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma where surgery and/or radiation therapy are not appropriate. Erivedge is the first licensed treatment in Australia for patients with advanced basal cell carcinoma (BCC +0.20%, news), a rare form of skin cancer which can be disfiguring, debilitating and even fatal.
Curis earned a $4 million milestone payment as a result of the TGA's approval of Erivedge and Curis is also entitled to receive royalties on Roche's future net sales of Erivedge in Australia.
"We are pleased with the TGA's decision to grant Erivedge approval in Australia and we view this milestone as continuing evidence of Roche's broad efforts to expand patient access to Erivedge," said Dan Passeri, Curis Chief Executive Officer. "We expect approval decisions in additional territories in 2013, including in the European Union after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP 0.00%, news) issued a positive opinion on approvability. We also expect that Roche will continue making global submissions seeking marketing approval for Erivedge in several territories in the coming months."
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on May 22, 2013 12:57:07 GMT -5
Nuvilex, Inc.(NVLX) operates independently and through wholly owned subsidiaries, that brings to market scientifically derived products designed to improve the health and well-being. It is a biotechnology and life technology company. Nuvilex manufactures, directly or indirectly through independent contractors Cinnergen, Cinnechol, Infinitink (and related private label ink products), and Talysn Scar Cream. The Company is also engaged in the research and development of Oraphyte, a non-toxic, biodegradable nematocide for use on turfgrass and crops, as well as Citroxin, is a natural, eco-friendly surface cleaner. Sales of I-Boost Immune Bars were discontinued in May 2009. The subsidiaries of the Company include Knock-Out Technologies, Ltd., MedElite, Inc., Cinnergen, Inc., I-Boost, Inc., Cinnechol Inc., Freedom-2 GmbH, Berlin, Freedom-2 Creditor Partners, Freedom-2 Holdings, Inc, Freedom-2, Inc., Exceptional Equipment and Ink Supply Company, Inc. they are going to start a phase III trail on medical pot for cancer patiences with the FDA approval
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Jun 12, 2013 8:00:57 GMT -5
Biodel Inc. (Biodel)BIOD: is a development-stage speciality biopharmaceutical company focused on the development and commercialization of treatments for diabetes. The Company develops its product candidates by applying its formulation technologies to existing drugs. Its advanced program involves developing formulations of injectable recombinant human insulin (RHI). In addition to its ultra-rapid-acting insulin formulations, the Company has developed prototype formulations of a liquid glucagon, a basal insulin and a glucose responsive insulin, in each case for use by patients with diabetes. RHI-based formulation known as Linjeta was the subject of a New Drug Application (NDA).
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Jun 25, 2013 13:31:32 GMT -5
Aethlon Medical, Inc.(AEMD) a development stage medical device company, focuses on creating devices for the treatment of cancer, infectious diseases, and other life-threatening conditions. It develops Aethlon Hemopurifier, a medical device that removes viral pathogens, immunosuppressive glycoproteins, and exosomes from the circulatory system. The companys Aethlon Hemopurifier is intended for the treatment of cancer, hepatitis-C virus, human immunodeficiency virus (HIV), and bioterror and pandemic threats. It also develops ELLSA, an enzyme linked lectin specific assay to identify the presence of exosomes underlying the HIV, tuberculosis, and various types of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal. The company was founded in 1991 and is based in San Diego, California.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Jul 8, 2013 8:53:29 GMT -5
Anavex Life Sciences Corp. AVXL: is a pharmaceutical company engaged in the development of novel drug candidates. ANAVEX 2-73, a drug candidate developed to treat Alzheimer's disease through disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg. Conducted pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Jul 23, 2013 13:37:37 GMT -5
Star Scientific (STSI): Star Scientific Inc. is engaged in the development of dissolvable smokeless tobacco products that deliver fewer carcinogenic toxins through the utilization of the innovative StarCured tobacco curing technology
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Aug 5, 2013 14:03:12 GMT -5
ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced initiation of a phase I clinical trial of cancer vaccine ICT-121 as a potential treatment for patients with recurrent glioblastoma multiforme (GBM). The investigator-sponsored phase I trial is being conducted at Cedars-Sinai Medical Center in Los Angeles, CA, by Jeremy Rudnick, MD, and ImmunoCellular is supporting the trial by providing the ICT-121 vaccine. ICT-121 is a dendritic cell vaccine targeting CD133, an important cancer stem cell marker that is commonly overexpressed on a broad range of solid tumors.
The primary objective of the open label phase I trial is to assess the safety and tolerability of ICT-121. Secondary objectives include overall survival (OS) and progression-free survival (PFS) at six months after surgery as well as other response parameters. Approximately 20 patients who have had gross tumor resection and experience a first recurrence of GBM, and who are HLA-A2 positive, will be treated in the trial. Patients will be administered the vaccine once per week for four weeks during the induction phase, followed by a maintenance phase consisting of one treatment every two months until their supply of vaccine is depleted or they experience progressive disease.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Aug 14, 2013 13:26:57 GMT -5
IsoRay, Inc.ISR: was organized under Minnesota law in 1983, formerly known as Century Park Pictures Corporation On July 28, 2005, Century changed its name to IsoRay, Inc. The Company provides treatment for all solid tumor applications using Cesium-131 (Cs-131). Such applications include prostate cancer; ocular melanoma; head, neck and lung tumors; and breast, liver, brain and pancreatic cancer. The professional and patient market segments each play a role in the ultimate choice of cancer treatment and the specific isotope chosen for seed brachytherapy treatment. In August 2009, IsoRay Medical obtained treatment for Proxcelan(tm) Cesium-131 brachytherapy seeds that are preloaded into bioabsorbable braided strands. Brachytherapy seeds are small devices used in a radiation procedure. IsoRay markets the Proxcelan Cs-131 brachytherapy seed for the treatment of prostate cancer, ocular melanomas, and head and neck cancers, and intends to market Cs-131 for the treatment of other malignant disease, such as lung, in the near future. The Company competes with both public and private medical device, biotechnology and pharmaceutical companies. The disposal of certain radioactive substances and wastes are subject to regulation by several federal and state agencies depending on the nature of the substance or waste material.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Aug 29, 2013 12:29:32 GMT -5
Chelsea Therapeutics International, Ltd.CHPT, is a specialty pharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products. The Company's currently licensed compounds target a variety of prevalent medical conditions; particularly rheumatoid arthritis, psoriasis, cancer, other immunological disorders, neurogenic orthostatic hypotension and other autonomic disorders. The Company is developing droxidopa, an orally active synthetic precursor of norepinephrine and its investigational product candidate, for the treatment of neurogenic orthostatic hypotension (NOH). It is currently focusing the majority of its drug development resources on two clinical stage development projects: droxidopa for symptomatic neurogenic orthostatic hypotension and other potential indications; and its portfolio of non-metabolized antifolate compounds for the treatment of rheumatoid arthritis. Droxidopa, a synthetic amino acid, is converted by the body into norepinephrine and, as a prodrug of norepinephrine, provides replacement therapy for norepinephrine deficiency. Norepinephrine is both a hormone and a neurotransmitter. As a hormone, secreted by the adrenal gland, it works alongside epinephrine/adrenaline to give the body sudden energy in times of stress, known as the ‘fight or flight’ response. As a neurotransmitter, it passes nerve impulses from one neuron to the next. While norepinephrine, as a catecholamine does not penetrate the blood-brain barrier, droxidopa, as a neutral amino acid, is able to do so thus providing both a peripheral and central effect on circulating norepinephrine levels. The FDA and foreign regulatory agencies regulate many aspects of product development and marketing of its product candidates including research, development, manufacture, labeling, promotion, advertising, distribution, and marketing.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Sept 17, 2013 8:55:04 GMT -5
GTx, Inc.(GTXI) is a Delaware corporation incorporated on September 24, 1997. It operates as a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical conditions. The Company develops selective androgen receptor modulators, or SARMs, to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). They are conducting the POWER 1 and POWER 2 (Prevention and treatment Of muscle Wasting in patients with cancER) pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer. The company is developing GTx-758, an oral luteinizing hormone, or LH, inhibitor for the treatment of advanced prostate cancer. In preclinical in vitro and in vivo models, GTx-758 has demonstrated the potential to reduce testosterone to castrate levels without causing certain estrogen deficiency side effects such as bone loss and hot flashes. The company’s most advanced product candidate, toremifene, is being developed for the prevention of bone fractures and treatment of other estrogen deficiency side effects of ADT in men with prostate cancer and for the prevention of prostate cancer in high risk men with high grade PIN. Additionally the company is developing Capesaris® (GTx-758), an oral nonsteroidal selective estrogen receptor (ER) alpha agonist, for secondary hormonal therapy in men with metastatic castration resistant prostate cancer, or CRPC, and, potentially, as a primary treatment for advanced prostate cancer used in combination with androgen deprivation therapy, or ADT. It faces competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions. It plans to build a specialty sales and marketing infrastructure, for marketing its products.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Oct 2, 2013 8:08:24 GMT -5
DURECT Corporation DRRX) was incorporated in Delaware in February 1998. The Company is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its proprietary drug delivery technology platforms. The Company’s product pipeline currently consists of seven investigational drug candidates in clinical development, with one program the subject of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA).The Company has other programs underway in fields outside of pain management, including several efforts underway which seek to improve the administration of biotechnology agents such as proteins and peptides. The Company’s development efforts are focused on the application of its pharmaceutical systems technologies to potential products in a variety of chronic and episodic disease areas including pain, central nervous system (CNS) disorders, cardiovascular disease and other chronic diseases. Its product candidate include Remoxy (Oral controlled release oxycodone); POSIDUR (Controlled release injection of bupivacaine); ELADUR (Transdermal bupivacaine); TRANSDUR-Sufentanil (Transdermal sufentanil); ORADUR-based opioid (hydrocodone); ORADUR-based opioid (hydromorphone); ORADUR-ADHD; ORADUR-based opioid (oxymorphone); and Relday (risperidone). The DURECT Solutions is the Company’s developing and commercializing pharmaceutical systems that will deliver the right drug to the right place, in the right amount and at the right time to treat chronic and episodic diseases and conditions. Its pharmaceutical systems enable optimized therapy for a given disease or patient population by controlling the rate and duration of drug administration. The Company has several major technology platforms: Bioerodible Injectable Depot Systems, The TRANSDUR Transdermal Delivery System, The ORADUR Sustained Release Gel Cap Technology, and The DURIN Biodegradable Implant Technology. The manufacture and marketing of its pharmaceutical systems
|
|
bimetalaupt
Senior Member
Joined: Oct 9, 2011 20:29:23 GMT -5
Posts: 2,325
|
Post by bimetalaupt on Oct 2, 2013 13:45:51 GMT -5
DURECT Corporation DRRX) was incorporated in Delaware in February 1998. The Company is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its proprietary drug delivery technology platforms. The Company’s product pipeline currently consists of seven investigational drug candidates in clinical development, with one program the subject of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA).The Company has other programs underway in fields outside of pain management, including several efforts underway which seek to improve the administration of biotechnology agents such as proteins and peptides. The Company’s development efforts are focused on the application of its pharmaceutical systems technologies to potential products in a variety of chronic and episodic disease areas including pain, central nervous system (CNS) disorders, cardiovascular disease and other chronic diseases. Its product candidate include Remoxy (Oral controlled release oxycodone); POSIDUR (Controlled release injection of bupivacaine); ELADUR (Transdermal bupivacaine); TRANSDUR-Sufentanil (Transdermal sufentanil); ORADUR-based opioid (hydrocodone); ORADUR-based opioid (hydromorphone); ORADUR-ADHD; ORADUR-based opioid (oxymorphone); and Relday (risperidone). The DURECT Solutions is the Company’s developing and commercializing pharmaceutical systems that will deliver the right drug to the right place, in the right amount and at the right time to treat chronic and episodic diseases and conditions. Its pharmaceutical systems enable optimized therapy for a given disease or patient population by controlling the rate and duration of drug administration. The Company has several major technology platforms: Bioerodible Injectable Depot Systems, The TRANSDUR Transdermal Delivery System, The ORADUR Sustained Release Gel Cap Technology, and The DURIN Biodegradable Implant Technology. The manufacture and marketing of its pharmaceutical systems THEY HAVE SOLD A LOT OF SHARES!! FLOAT ??
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Nov 5, 2013 15:02:48 GMT -5
yea i would say there is some float but I still think there is also a lot of upside left.
Pacific Biosciences of California, Inc.:PACB, was incorporated in the State of Delaware in 2000. The Company’s aim is to transform the way humankind acquires, processes and interprets data from living systems through the design, development and commercialization of innovative tools for biological research. To achieve this it has created a powerful platform called SMRT technology. Its initial focus is to use its SMRT technology in the DNA sequencing market where it has developed and are preparing to commercialize its first product, the PacBio RS, a novel third generation sequencing platform. The PacBio RS consists of an instrument platform that uses its proprietary consumables, including its SMRT Cells and reagent kits, providing a complete solution to the customer. The Company’s strategy includes defining the future of biological analysis based on SMRT technology, focus initially on the DNA sequencing market, continually enhance product performance to increase market share, leverage platform to develop and launch additional applications, create a global community of users to enhance informatics capabilities and drive adoption of its products. The Company’s competitors include Illumina Inc., Life Technologies Corporation and Roche Applied Science. The Company markets its products through a direct sales force in North America and the United Kingdom. The Company has received orders for its limited production release instrument from Baylor College of Medicine, the Broad Institute of MIT and Harvard, Cold Spring Harbor Laboratory, the U.S. Department of Energy Joint Genome Institute, The Genome Center at Washington University, Monsanto Company, the National Cancer Institute/SAIC-Frederick, the National Center for Genome Resources, the Ontario Institute for Cancer Research, Stanford University and Wellcome Trust Sanger Institute.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Dec 7, 2013 14:57:16 GMT -5
Green Automotive Company:GACR, is a state-of-the-art vehicle design, engineering, manufacturing and distribution company, driving innovation in the use of leading edge zero and low emission technologies. We also provide a comprehensive after sales program maximizing the life time value of clean transport solutions. Green Automotive Company possesses a unique portfolio of innovative businesses and is active in 3 main market segments: Cutting edge technology development, engineering & design with a focus on zero and low emission vehicle solutions, Manufacturing and customization of vehicles for niche markets with the potential to be converted into low emission or electric vehicles and After sales services for electric or low emission vehicles including servicing and repair.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Dec 30, 2013 15:28:47 GMT -5
INO:is engaged in the development of a new generation of vaccines and immune therapies, called synthetic vaccines, focused on cancers and infectious diseases. Its DNA-based SynCon® technology is designed to provide universal protection against known as well as new unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with its proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Its preclinical development and clinical programs include cervical dysplasia/cancer (therapeutic), influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. The Company faces competition from several development-stage and established enterprises, including major pharmaceutical and biotechnology firms, which are actively engaged in infectious disease and cancer vaccine research and development. Any pharmaceutical products that the Company develops will require regulatory clearances prior to clinical trials and additional regulatory approvals prior to commercialization. As of March 8, 2013, the Company’s patent portfolio included over 68 issued United States patents and 214 issued foreign counterpart patents.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Jan 25, 2014 15:02:39 GMT -5
Elite Pharmaceuticals, Inc. (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy volunteers for an undisclosed opioid abuse deterrent product utilizing Elite's proprietary pharmacological abuse deterrent technology.
The study is a single-dose, open-label, partially randomized, three-way crossover study in which 52 healthy adult subjects will receive treatment in a partially randomized sequence. The primary objective of this study is to compare the bioavailability of the Company's abuse deterrent product to that from the reference listed drug under fasted and fed conditions. The secondary objectives are: (i) determine whether or not subjects receiving the Company's formulation are exposed to naltrexone; (ii) evaluate the safety and tolerability of the Company's product.
"Abuse of prescription narcotics is a serious problem in our society and we believe that our pharmacological approach provides a higher barrier to abuse than a physical approach," said Nasrat Hakim, President and CEO of Elite. "We are pleased to announce initiation of this pivotal study for this undisclosed proprietary opioid abuse deterrent product. The dosing of our pilot study for our extended release oxycodone product has also been completed and we await final results from that study."
The bioequivalence studies for these opioid abuse deterrent products are being conducted under the direction of Camargo Pharmaceutical Services.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Mar 5, 2014 10:49:33 GMT -5
Atlantic Power Corporation:AT, is a corporation established under the laws of the Province of Ontario, Canada on June 18, 2004 and continued to the Province of British Columbia on July 8, 2005.. The Company is a power generation and infrastructure Company with a well-diversified portfolio of assets in the United States and Canada. Its power generation projects sell electricity to utilities and other large commercial customers largely under long-term power purchase agreements, which seek to minimize exposure to changes in commodity prices . The Company’s current portfolio of continuing operations consists of interests in twenty-nine operational power generation projects across eleven states in the United States and two provinces in Canada. In addition, the Company have one 53 MW biomass project under construction in Georgia. The Company develop, construct, and operate wind and solar energy projects across the United States and Canada. The Company sell the capacity and energy from its power generation projects under PPAs to a variety of utilities and other parties. The Company also partner with recognized leaders in the independent power industry to operate and maintain other projects, including Colorado Energy Management ("CEM"), Power Plant Management Services ("PPMS") and Delta Power Services ("DPS"). Under these operation, maintenance and management agreements, the operator is typically responsible for operations, maintenance and repair services
|
|